Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000594917 | SCV000702511 | uncertain significance | not provided | 2016-10-18 | criteria provided, single submitter | clinical testing | |
Invitae | RCV001043387 | SCV001207131 | uncertain significance | Autosomal recessive limb-girdle muscular dystrophy type 2A | 2021-08-13 | criteria provided, single submitter | clinical testing | This sequence change replaces glutamic acid with lysine at codon 257 of the CAPN3 protein (p.Glu257Lys). The glutamic acid residue is highly conserved and there is a small physicochemical difference between glutamic acid and lysine. This variant is not present in population databases (ExAC no frequency). This missense change has been observed in individual(s) with clinical features of CAPN3-related conditions (PMID: 30564623). ClinVar contains an entry for this variant (Variation ID: 497796). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Natera, |
RCV001043387 | SCV001454326 | uncertain significance | Autosomal recessive limb-girdle muscular dystrophy type 2A | 2020-09-16 | no assertion criteria provided | clinical testing |